Genome-Wide Association Study of Sepsis Susceptibility in ICU Patients Identifies Arab Founder Loss-of-Function Variant in UBE2L3
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Sepsis causes approximately 11 million deaths globally each year. Whole-genome sequencing (WGS) of founder populations offers a unique opportunity for discovery of genes related to susceptibility of sepsis. We performed GWAS and EXWAS on WGS data for n=210 Arab ICU patients (n=68 sepsis cases, n=142 controls, other ICU-related disorders) and prioritized n=40 associated deleterious founder variants in n=31 genes (REGENIE Firth regression p < 0.05; CADD score > 20; enriched AAF vs AllofUs/gnomAD), including a novel start-loss variant in UBE2L3 (c.2T>G; p.Met1?; CADD = 25.6; SIFT = 0.001) in sepsis cases (3/68 vs 0/142 controls; Fisher’s exact P = 0.026). In All of Us (AoU), UBE2L3 missense burden was associated with bacterial infection (n=26,939 cases; SKAT-O P = 2.38×10⁻³; OR=23.10; 95% CI = [0.63–845.27]). LLM AI models fine-tuned for drug development scored UBE2L3 a 7.8 of 10 as a drug target for sepsis, consistent with mouse UBE2L3 KO showing increased IL-1Beta mediated inflammation in sepsis.
